CBS NewsSig. 6NewsHealthEconomy
Her son was dying, but his rare cancer made it difficult to get the right drug
A young man with a rare brain cancer was prescribed an off-label drug that his doctors believed was biologically reasonable, but his pharmacy benefit manager and county health plan refused coverage and the manufacturer declined to donate it. The article uses his family’s story to illustrate how insurers rely on FDA labels and guidelines that often do not exist for rare cancers, leaving patients facing steep costs or going without.
